alliancerm.org Open in urlscan Pro
141.193.213.10  Public Scan

Form analysis
2 forms found in the DOM

https://alliancerm.org

<form action="https://alliancerm.org" class="padding-box">
  <div class="grid-x align-middle">
    <div class="cell auto text-center">
      <input type="search" name="s" placeholder="Search Alliance for Regenerative Medicine">
      <input type="submit" class="button no-margin hollow small" value="Search">
    </div>
  </div>
</form>

https://alliancerm.org

<form class="" action="https://alliancerm.org">
  <div class="grid-x grid-padding-x">
    <div class="cell auto">
      <label for="s">Query</label>
      <input type="search" name="s" placeholder="Search">
    </div>
    <div class="cell shrink">
      <label for="swpengine">Search Engine</label>
      <select name="swpengine" id="">
        <option value="default" selected="selected"> Default </option>
        <option value="management"> Management </option>
      </select>
    </div>
  </div>
  <div class="grid-x">
    <div class="cell text-center">
      <input type="submit" class="button">
    </div>
  </div>
</form>

Text Content

Manage consent
We use cookies to optimize our website and our service. Cookies & Personal
Information - Privacy statement
Accept
 * GROW Internship Program
 * ARM MembersToggle menu
   * Members & Profiles
   * Benefits of Membership
   * Committees & Task Forces
   * Become a Member
 * ImpactToggle menu
   * ARM’s Impact
   * Our FocusToggle menu
     * Market Access
     * RegulatoryToggle menu
       * Regulatory
       * Gene Editing
       * Stem Cell Clinics
     * Manufacturing
     * Education & Information
     * Capital Formation
   * Committees & Task Forces
 * Regenerative MedicineToggle menu
   * Technologies
   * Available Products
   * Genome Editing
   * Clinical Data & Events
   * Expedited Approval Designations
 * EventsToggle menu
   * ARM EventsToggle menu
     * ARM Webinar Series
     * State of the Industry
     * Meeting on the Med
     * Congressional Fly-In
     * Meeting on the Mesa
     * Past ARM Events
   * Other Industry Events
 * For the MediaToggle menu
   * Press Releases
   * Publications & Presentations
   * Fact Sheet
   * In the News
   * EU Market Access Report
 * About ARMToggle menu
   * Officers and Board of Directors
   * Committees & Task Forces
   * ARM’s Impact
   * ARM Staff
   * Fact Sheet
   * Jobs at ARM
 * Publications & PresentationsToggle menu
   * Q3 2021 Trend Talk
   * Recently Released
   * Archived
 * Contact
 * ARM Foundation


 * 
 * 
 * 
 * 






WE SUPPORT THE DEVELOPMENT OF SAFE AND EFFECTIVE REGENERATIVE MEDICINES AND
ADVANCED THERAPIES WORLDWIDE.

The Alliance for Regenerative Medicine (ARM) is the leading international
advocacy organization dedicated to realizing the promise of regenerative
medicines and advanced therapies. As the global voice of the sector, ARM
represents the interests of 400+ members across 25 countries, including small
and large companies, academic research institutions, major medical centers and
patient groups.

Learn More

Become A Member

 





 

JOIN ARM AT THE MEETING ON THE MED!

Registration is now open for the 2022 Meeting on the Med! The meeting, which
runs from April 20-22, takes place in Barcelona, with virtual attendance options
for registrants who can’t make it in person. Learn more!

Looking for updates on future ARM events? Sign up for our email list here!



FEATURED


ARM LAUNCHES GROW REGENMED INTERNSHIP PROGRAM

Thanks to the work of ARM ‘Action for Equality’ Task Force, ARM is launching the
GROW RegenMed Internship Program to provide crucial, early-career paid
opportunities in the regenerative medicine sector, initially to Black students
and over time to a broader minority population.


Learn More

FEATURED


PROJECT A-GENE

The Alliance for Regenerative Medicine (ARM) and the National Institute for
Innovation in Manufacturing Biopharmaceuticals (NIIMBL) released Project A-Gene,
a multistakeholder collaboration to incorporate Quality by Design (QbD)
principles into a manufacturing case study of a viral vector commonly used in
gene therapies.

View A-Gene

FEATURED


REGENERATIVE MEDICINE: NEW PARADIGMS

2021 was an auspicious year for the cell and gene therapy sector. ARM shared
highlights from the investment, clinical, and scientific landscape, as well as a
look at what’s ahead for 2022 and beyond, at the Cell & Gene Therapy State of
the Industry Briefing. Following the presentation, two expert led panels
discussed gene therapy for rare disease and next-generation therapies for
cancer.

 

Watch the Recording

FEATURED


ARM LAUNCHES GROW REGENMED INTERNSHIP PROGRAM

Thanks to the work of ARM ‘Action for Equality’ Task Force, ARM is launching the
GROW RegenMed Internship Program to provide crucial, early-career paid
opportunities in the regenerative medicine sector, initially to Black students
and over time to a broader minority population.


Learn More

FEATURED


PROJECT A-GENE

The Alliance for Regenerative Medicine (ARM) and the National Institute for
Innovation in Manufacturing Biopharmaceuticals (NIIMBL) released Project A-Gene,
a multistakeholder collaboration to incorporate Quality by Design (QbD)
principles into a manufacturing case study of a viral vector commonly used in
gene therapies.

View A-Gene

FEATURED


REGENERATIVE MEDICINE: NEW PARADIGMS

2021 was an auspicious year for the cell and gene therapy sector. ARM shared
highlights from the investment, clinical, and scientific landscape, as well as a
look at what’s ahead for 2022 and beyond, at the Cell & Gene Therapy State of
the Industry Briefing. Following the presentation, two expert led panels
discussed gene therapy for rare disease and next-generation therapies for
cancer.

 

Watch the Recording

FEATURED


ARM LAUNCHES GROW REGENMED INTERNSHIP PROGRAM

Thanks to the work of ARM ‘Action for Equality’ Task Force, ARM is launching the
GROW RegenMed Internship Program to provide crucial, early-career paid
opportunities in the regenerative medicine sector, initially to Black students
and over time to a broader minority population.


Learn More





FOLLOW ARM ON TWITTER

 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 6 days ago

To date, 7 approved #ATMPs have been withdrawn from the European market. So what
does it take to successfully commercialize in Europe? Experts from...
5 4
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 7 days ago

Centuries after cells were first observed, biologists are discovering their true
nature—and learning to build their own. These discoveries could help...
3 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 7 days ago

ARM Director of Public Affairs @SMajorsDC discusses the successes of the
#cellandgenetherapy sector & explains how practices learned during the...
3 3
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 8 days ago

New data from @intelliatx & @Regeneron's in vivo #CRISPR #geneediting therapy
for a #raredisease affecting the liver showed that a higher dose...
2 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 8 days ago

THE @US_FDA has approved the 6th #CARTcell therapy in the US, the 2nd to be
approved for #multiplemyeloma. 78% of patients who received...
6 2
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 9 days ago

The #BespokeGeneTherapyConsorium, managed by @FNIH_Org, aims to reduce costs and
encourages the development of #GeneTherapies for rare genetic...
5 2
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 9 days ago

There are 300 million people living with a #raredisease — including an estimated
25-30 million in the US, according to @RareDiseases, & 30...
8 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 12 days ago

Welcome to our new ARM members for the month of February! We look forward to
working with you to accelerate #patientaccess to #cellandgenetherapy....
1 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 7 hours ago

Researchers from @RiceUniversity have created beadlike implants to deliver cells
engineered to produce IL-2, a cytokine that helps the immune system...
1 3
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 9 hours ago

ARM & our members are investing in future Black leaders in #cellandgenetherapy
via our GROW #Internship program. But supporting new leaders is...
0 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) a day ago

What's next for #geneediting? Multiplexing has the potential to allow developers
to tackle polygenic diseases, speed up the development of...
2 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) a day ago

As the #genetherapy field matures, dosing & delivery takes center stage. While
many developers are pursuing nonviral delivery methods, others...
1 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 2 days ago

' @BayerPharma announced it will invest $1.6B in manufacturing facilities in
Germany, with a focus on #cellandgenetherapy and data analytics. Large...
4 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 2 days ago

European #cellandgenetherapy developers raised $3.3B in financing in 2021. But
what can we expect from the investment environment in 2022 and beyond?...
3 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 5 days ago

The principles of synthetic biology could one day be combined with #genetherapy
to engineer cells with high levels of gene expression, or with...
5 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 5 days ago

#CRISPR technology is moving from concept to clinic at a breathtaking pace.
Though it will take years to learn whether this can be a lifelong fix,...
1 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 6 days ago

To date, 7 approved #ATMPs have been withdrawn from the European market. So what
does it take to successfully commercialize in Europe? Experts from...
5 4
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 7 days ago

Centuries after cells were first observed, biologists are discovering their true
nature—and learning to build their own. These discoveries could help...
3 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 7 days ago

ARM Director of Public Affairs @SMajorsDC discusses the successes of the
#cellandgenetherapy sector & explains how practices learned during the...
3 3
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 8 days ago

New data from @intelliatx & @Regeneron's in vivo #CRISPR #geneediting therapy
for a #raredisease affecting the liver showed that a higher dose...
2 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 8 days ago

THE @US_FDA has approved the 6th #CARTcell therapy in the US, the 2nd to be
approved for #multiplemyeloma. 78% of patients who received...
6 2
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 9 days ago

The #BespokeGeneTherapyConsorium, managed by @FNIH_Org, aims to reduce costs and
encourages the development of #GeneTherapies for rare genetic...
5 2
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 9 days ago

There are 300 million people living with a #raredisease — including an estimated
25-30 million in the US, according to @RareDiseases, & 30...
8 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 12 days ago

Welcome to our new ARM members for the month of February! We look forward to
working with you to accelerate #patientaccess to #cellandgenetherapy....
1 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 7 hours ago

Researchers from @RiceUniversity have created beadlike implants to deliver cells
engineered to produce IL-2, a cytokine that helps the immune system...
1 3
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 9 hours ago

ARM & our members are investing in future Black leaders in #cellandgenetherapy
via our GROW #Internship program. But supporting new leaders is...
0 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) a day ago

What's next for #geneediting? Multiplexing has the potential to allow developers
to tackle polygenic diseases, speed up the development of...
2 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) a day ago

As the #genetherapy field matures, dosing & delivery takes center stage. While
many developers are pursuing nonviral delivery methods, others...
1 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 2 days ago

' @BayerPharma announced it will invest $1.6B in manufacturing facilities in
Germany, with a focus on #cellandgenetherapy and data analytics. Large...
4 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 2 days ago

European #cellandgenetherapy developers raised $3.3B in financing in 2021. But
what can we expect from the investment environment in 2022 and beyond?...
3 0
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 5 days ago

The principles of synthetic biology could one day be combined with #genetherapy
to engineer cells with high levels of gene expression, or with...
5 1
 * 
 * 
 * 

Alliance for Regenerative Medicine (ARM) 5 days ago

#CRISPR technology is moving from concept to clinic at a breathtaking pace.
Though it will take years to learn whether this can be a lifelong fix,...
1 0





LEARN ABOUT REGENERATIVE MEDICINE

Regenerative medicine includes gene therapies, cell therapies, and
tissue-engineered products intended to augment, repair, replace, or regenerate
organs, tissues, cells, genes, and metabolic processes in the body.

Regenerative medicine aims to alter the current practice of medicine by treating
the root causes of disease and disorders.

 



FIND OUT MORE

 * Technologies
 * Available Products
 * Latest Sector Data
 * ARM Foundation
 * Publications & Presentations




DISCOVER THE ALLIANCE

ARM takes the lead on the most important issues facing the regenerative medicine
and advanced therapy sector today:

 * Advocating for clear, predictable and harmonized regulatory and review
   pathways
 * Enabling market access and value-based reimbursement policies
 * Addressing industrialization and manufacturing hurdles
 * Conducting key stakeholder outreach, communication and education
 * Facilitating sustainable access to capital and identify sources of potential
   public funding.



FIND OUT MORE

 * 2019 Annual Report
 * Benefits of Membership
 * ARM’s Impact
 * ARM Committees
 * Officers & Board of Directors
 * Staff
 * ARM Fact Sheet


EXPLORE HOW ARM LEADS THE WAY

ARM is a global community of therapeutic companies small & large, non-profit
research institutions, patient organizations, and tool and technology providers.
Working with our members and policymakers, we foster investment, research &
development, and the successful commercialization of safe and effective
treatments and cures for patients around the world.

FIND OUT MORE

 * Regulatory
 * Market Access & Value
 * Manufacturing & CMC
 * Genome Editing
 * ARM Committees
 * ARM Foundation




STAY CONNECTED

Newsletter Sign Up Twitter LinkedIn





ALLIANCE FOR REGENERATIVE MEDICINE

 * News
 * Events

 * 
 * 
 * 

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

--------------------------------------------------------------------------------



2-4 Schuman Roundabout
B-1040 Brussels
Belgium

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

2-4 Schuman Roundabout
B-1040 Brussels
Belgium

SOCIAL

 * 
 * 
 * 



LATEST

 * News
 * Events

STAY CONNECTED

 * Newsletter Sign Up





SEARCH ARM





SEARCH

Query
Search Engine Default Management

×